Theravance Biopharma, Inc. (TBPH)

Market Cap	1.01B
Revenue (ttm)	80.33M
Net Income (ttm)	29.34M
Shares Out	50.67M
EPS (ttm)	0.58
PE Ratio	34.40
Forward PE	26.67
Dividend	n/a
Ex-Dividend Date	n/a

Volume	845,288
Open	19.84
Previous Close	18.94
Day's Range	19.38 - 20.28
52-Week Range	7.90 - 20.28
Beta	0.18
Analysts	Strong Buy
Price Target	28.00 (+40.28%)
Earnings Date	Nov 10, 2025

About TBPH

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the de...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 97
• Stock Exchange: NASDAQ
• Ticker Symbol: TBPH
• Website: https://www.theravance.com

Financial Performance

In 2024, Theravance Biopharma's revenue was $64.38 million, an increase of 12.12% compared to the previous year's $57.42 million. Losses were -$56.42 million, 2.22% more than in 2023.

Analyst Summary

According to 4 analysts, the average rating for TBPH stock is "Strong Buy." The 12-month stock price target is $28.0, which is an increase of 40.28% from the latest price.

Price Target

$28.0

(40.28% upside)

Analyst Consensus: Strong Buy